milrinone lactate injection VIAL Dosage and Administration

()

DOSAGE AND ADMINISTRATION

Milrinone lactate injection should be administered with a loading dose followed by a continuous infusion (maintenance dose) according to the following guidelines:

LOADING DOSE  

50 mcg/kg: Administer slowly over 10 minutes

The table below shows the loading dose in milliliters (mL) of Milrinone lactate injection (1mg/mL) by patient body weight (kg).

Loading Dose (mL) Using 1 mg/mL Concentration

Patient Body Weight (kg)

kg

30

40

50

60

70

80

90

100

110

120

mL

1.5

2

2.5

3

3.5

4

4.5

5

5.5

6

The loading dose may be given undiluted, but diluting to a rounded total volume of 10 or 20 mL (see Maintenance Dose for diluents) may simplify the visualization of the injection rate.

MAINTENANCE DOSE

 



Infusion Rate

Total Daily
Dose

(24 hours)

 

Minimum

0.375 mcg/kg/min

0.59 mg/kg

Administer as a continuous intravenous infusion.

Standard

0.5 mcg/kg/min

0.77 mg/kg

Maximum

0.75 mcg/kg/min

1.13 mg/kg

Milrinone lactate injection drawn from vials should be diluted prior to maintenance dose administration. The diluents that may be used are 0.45% Sodium Chloride Injection, USP; 0.9% Sodium Chloride Injection, USP; or 5% Dextrose Injection, USP. The table below shows the volume of diluent in milliliters (mL) that must be used to achieve 200 mcg/mL concentration for infusion, and the resultant total volumes.

Desired Infusion

Concentration

mcg/mL

Milrinone

1 mg/mL

(mL)

Diluent

(mL)

Total Volume

(mL)

200

10

40

50

200

20

80

100

The infusion rate should be adjusted according to hemodynamic and clinical response. Patients should be closely monitored. In controlled clinical studies, most patients showed an improvement in hemodynamic status as evidenced by increases in cardiac output and reductions in pulmonary capillary wedge pressure.

Note: See " Dosage Adjustment in Renally Impaired Patients ." Dosage may be titrated to the maximum hemodynamic effect and should not exceed 1.13 mg/kg/day. Duration of therapy should depend upon patient responsiveness.

The maintenance dose in mL/hr by patient body weight (kg) may be determined by reference to the following table.

Milrinone Infusion Rate (mL) Using 200 mcg/mL Concentration

Maintenance Dose

(mcg/kg/min)

Patient Body Weight (kg)

30

40

50

60

70

80

90

100

110

120

0.375

3.4

4.5

5.6

6.8

7.9

9

10.1

11.3

12.4

13.5

0.4

3.6

4.8

6

7.2

8.4

9.6

10.8

12

13.2

14.4

0.5

4.5

6

7.5

9

10.5

12

13.5

15

16.5

18

0.6

5.4

7.2

9

10.8

12.6

14.4

16.2

18

19.8

21.6

0.7

6.3

8.4

10.5

12.6

14.7

16.8

18.9

21

23.1

25.2

0.75

6.8

9

11.3

13.5

15.8

18

20.3

22.5

24.8

27

When administering milrinone lactate by continuous infusion, it is advisable to use a calibrated electronic infusion device.

Dosage Adjustment in Renally Impaired Patients

Data obtained from patients with severe renal impairment (creatinine clearance = 0 to 30 mL/min) but without congestive heart failure have demonstrated that the presence of renal impairment significantly increases the terminal elimination half-life of milrinone. Reductions in infusion rate may be necessary in patients with renal impairment. For patients with clinical evidence of renal impairment, the recommended infusion rate can be obtained from the following table:

Creatinine Clearance Infusion Rate

Creatinine Clearance

(mL/min/1.73 m 2 )

Infusion Rate

(mcg/kg/min)

5

0.2

10

0.23

20

0.28

30

0.33

40

0.38

50

0.43

Intravenous drug products should be inspected visually and should not be used if particulate matter or discoloration is present.

Find milrinone lactate injection VIAL medical information:

Find milrinone lactate injection VIAL medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

milrinone lactate injection VIAL Quick Finder

Prescribing Information
Download Prescribing Information

Health Professional Information

Dosage and Administration

DOSAGE AND ADMINISTRATION

Milrinone lactate injection should be administered with a loading dose followed by a continuous infusion (maintenance dose) according to the following guidelines:

LOADING DOSE  

50 mcg/kg: Administer slowly over 10 minutes

The table below shows the loading dose in milliliters (mL) of Milrinone lactate injection (1mg/mL) by patient body weight (kg).

Loading Dose (mL) Using 1 mg/mL Concentration

Patient Body Weight (kg)

kg

30

40

50

60

70

80

90

100

110

120

mL

1.5

2

2.5

3

3.5

4

4.5

5

5.5

6

The loading dose may be given undiluted, but diluting to a rounded total volume of 10 or 20 mL (see Maintenance Dose for diluents) may simplify the visualization of the injection rate.

MAINTENANCE DOSE

 



Infusion Rate

Total Daily
Dose

(24 hours)

 

Minimum

0.375 mcg/kg/min

0.59 mg/kg

Administer as a continuous intravenous infusion.

Standard

0.5 mcg/kg/min

0.77 mg/kg

Maximum

0.75 mcg/kg/min

1.13 mg/kg

Milrinone lactate injection drawn from vials should be diluted prior to maintenance dose administration. The diluents that may be used are 0.45% Sodium Chloride Injection, USP; 0.9% Sodium Chloride Injection, USP; or 5% Dextrose Injection, USP. The table below shows the volume of diluent in milliliters (mL) that must be used to achieve 200 mcg/mL concentration for infusion, and the resultant total volumes.

Desired Infusion

Concentration

mcg/mL

Milrinone

1 mg/mL

(mL)

Diluent

(mL)

Total Volume

(mL)

200

10

40

50

200

20

80

100

The infusion rate should be adjusted according to hemodynamic and clinical response. Patients should be closely monitored. In controlled clinical studies, most patients showed an improvement in hemodynamic status as evidenced by increases in cardiac output and reductions in pulmonary capillary wedge pressure.

Note: See " Dosage Adjustment in Renally Impaired Patients ." Dosage may be titrated to the maximum hemodynamic effect and should not exceed 1.13 mg/kg/day. Duration of therapy should depend upon patient responsiveness.

The maintenance dose in mL/hr by patient body weight (kg) may be determined by reference to the following table.

Milrinone Infusion Rate (mL) Using 200 mcg/mL Concentration

Maintenance Dose

(mcg/kg/min)

Patient Body Weight (kg)

30

40

50

60

70

80

90

100

110

120

0.375

3.4

4.5

5.6

6.8

7.9

9

10.1

11.3

12.4

13.5

0.4

3.6

4.8

6

7.2

8.4

9.6

10.8

12

13.2

14.4

0.5

4.5

6

7.5

9

10.5

12

13.5

15

16.5

18

0.6

5.4

7.2

9

10.8

12.6

14.4

16.2

18

19.8

21.6

0.7

6.3

8.4

10.5

12.6

14.7

16.8

18.9

21

23.1

25.2

0.75

6.8

9

11.3

13.5

15.8

18

20.3

22.5

24.8

27

When administering milrinone lactate by continuous infusion, it is advisable to use a calibrated electronic infusion device.

Dosage Adjustment in Renally Impaired Patients

Data obtained from patients with severe renal impairment (creatinine clearance = 0 to 30 mL/min) but without congestive heart failure have demonstrated that the presence of renal impairment significantly increases the terminal elimination half-life of milrinone. Reductions in infusion rate may be necessary in patients with renal impairment. For patients with clinical evidence of renal impairment, the recommended infusion rate can be obtained from the following table:

Creatinine Clearance Infusion Rate

Creatinine Clearance

(mL/min/1.73 m 2 )

Infusion Rate

(mcg/kg/min)

5

0.2

10

0.23

20

0.28

30

0.33

40

0.38

50

0.43

Intravenous drug products should be inspected visually and should not be used if particulate matter or discoloration is present.

Resources

Didn’t find what you were looking for? Contact us.

MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985*

*Contact Medical Information. 8AM-9PM ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.

FDA Medwatch

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.